Momentum Relative Strength (%) 1m +201.3% 3m +456.2% 1yr +1.9% Volume Change (%) 10d v 3m +719.8% Price vs... (%) 52w High -27.6% 50d MA +179.5% 200d MA +258.6% 6 Piotroski F-Score -0.86 Altman Z1-Score 1864 34% D+ Health Trend Bankruptcy Risk Earnings Manipulation Risk Magic Formula Score NCYT 45.99p 8.0 21.0% Novacyt SA Highly Speculative , Micro Cap , Turnaround Market Cap Enterprise Value Revenue Market Cap Rank £14.3m £20.9m £11.7m 1452nd / 1833 Quality Value Momentum Stock Rank ™ 37 61 84 68 Zoom Mar '19 May '19 Jul '19 Sep '19 Nov '19 Jan '20 0 20 40 2018 2019 2020 1m 3m 6m YTD 1y 2y 3y 5y All vs. market vs. industry Growth & Value 12m Forecast Rolling PE Ratio (f) 3.23 PEG Ratio (f) 0.057 EPS Growth (f) 133.3 % Dividend Yield (f) n/a % Valuation (ttm) Price to Book Value 0.92 Price to Tang. Book n/a Price to Free Cashflow n/a Price to Sales 1.22 EV to EBITDA 22.7 Margin of Safety (beta) 88% 319% Broker Target Relative to Sector ◀ ▶ Screens Passed NCYT doesn't qualify for any screens. Find out why: View Checklists vs. market vs. industry Quality Return on Capital -2.36 % Return on Equity -7.11 % Operating Margin -3.88 % Balance Sheet · Income Statement · Cashflow Financial Summary Year End 31st Dec 2013 2014 2015 2016 2017 2018 TTM 2019E 2020E CAGR / Avg Revenue €m 1.15 4.53 8.89 11.1 12.7 13.7 13.9 21.0 28.0 +64.1% Operating Profit €m -1.00 -3.69 -13.2 -4.46 -2.12 -1.39 -0.54 Net Profit €m -1.00 -3.91 -13.9 -5.71 -5.44 -4.74 -4.89 2.20 3.00 EPS Reported € -0.34 -0.88 -2.05 -0.47 -0.15 -0.056 -0.037 EPS Normalised € -0.36 -0.86 -1.10 -0.45 -0.14 -0.049 -0.035 0.060 0.14 EPS Growth % +133.3 PE Ratio x n/a n/a 7.53 3.23 PEG x n/a n/a 0.057 n/a Profitability Operating Margin % -86.2 -81.6 -148.3 -40.3 -16.6 -10.1 -3.88 -63.9% ROA % -26.3 -63.6 -24.0 -10.8 -4.43 ROCE % -42.8 -17.2 -103.2 -20.6 -8.1 -6.1 -2.36 -33.0% ROE % -34.7 -90.3 -40.4 -16.4 -9.4 -7.11 -38.2% Cashflow Op. Cashflow ps € -0.28 -0.47 -0.79 -0.21 -0.20 -0.033 0.002 Capex ps € 0.20 0.12 0.12 0.045 0.042 0.018 0.022 -38.0% Free Cashflow ps € -0.48 -0.60 -0.91 -0.26 -0.24 -0.051 -0.020 Dividends Dividend ps € Dividend Growth % Dividend Yield % Dividend Cover x Balance Sheet Cash etc €m 1.00 2.34 1.69 2.87 4.36 1.14 0.61 +2.7% Working Capital €m 1.10 0.67 1.27 -1.46 3.13 -2.09 -3.95 Net Fixed Assets €m 0.17 0.61 0.94 1.28 1.81 3.72 6.24 +85.4% Net Debt €m -0.79 -1.32 1.68 4.34 -0.46 4.23 7.88 Book Value €m 2.25 20.3 10.5 17.8 24.9 20.1 18.5 +55.0% Average Shares m 2.93 4.44 6.79 12.1 23.1 37.7 30.4 +66.7% Book Value ps € 0.76 3.23 1.46 1.02 0.66 0.53 0.49 -6.8% D+ Liquidity (ttm) Curr. Ratio 0.65 Quick Ratio 0.44 Interest Cov. -0.71 Efficiency (ttm) Asset Turnover 0.42 Rec's Turnover 4.00 Stock Turnover 2.21 Other Ratios Leverage (ttm) total -intang +pension Gross Gearing % 45.9 45.9 Net Gearing % 42.6 42.6 Cash / Assets % 1.78 1.78 vs. market vs. industry Recent History Latest interim period (ended 30th Jun '19) vs. prior year Sales Growth 12.4 % EPS Growth n/a % 3yr Compound Annual Growth Rate Sales Growth 15.6 % EPS Growth n/a % DPS Growth n/a % Graphical History Current Fiscal Year 2019 Revenue 2013 2014 2015 2016 2017 2018 2019 2020 10m 20m 30m Net Profit 2013 2014 2015 2016 2017 2018 2019 2020 -10m -5m 5m Normalised EPS 2013 2014 2015 2016 2017 2018 2019 2020 -1 -0.5 0.5 PE Ratio Range 2014 2015 2016 2017 2018 2019 0 Dividend Yield Range 2014 2015 2016 2017 2018 2019 0 © Stockopedia 2020-02-03,12:04:43 No. of Shareholders: n/a Last Annual December 31st, 2018 Last Interim June 30th, 2019 Incorporated July 3, 2006 Public Since October 12, 2012 Shares in Issue 37,664,342 Free Float 35.8m (95.2%) Sector Healthcare Industry Biotechnology & Medical Research Index Exchange London Stock Exchange ( Dual Listing ) Eligible for an ISA? a SIPP? Novacyt SA is a France-based company that develops and markets solutions dedicated to the Jeld of liquid-based cytology and molecular biology. The Company develops a secure automated cytology named NovaPrep Processor System. Novacyt SA oKers a solution of cytological sampling to help in the detection of precancerous and cancerous lesions. The Company creates bottles speciJcally dedicated to the optimization of cell collection. The Company’s range of products includes Bottle Gyn and No Gyn Bottle. Novacyt SA is present in France and internationally through a network of over 10 distributors. Directors: Anthony Dyer (CFO) , Paul Eros (EXB) , Wendy Karban (CHO) , Graham Mullis (CEO) 54, Mandy Cowling (DIR) , Steve Gibson (EXB) , Jean-Pierre Crinelli (NED) 68, Ian Wilde (EXB) , James Wakefield (NEC) , Andrew Heath (NID) 70, Ruth Powell (EXB) , Phillip Sefton (EXB) , Juliet Thompson (NID) 52, Edwin Snape (NID) 79, No. of Employees: 119 Address 13 avenue Morane Saulnier, VELIZY VILLACOUBLAY, 78140, France Web https://novacyt.com/ Phone +33 1 39465104 Contact Graham Mullis (Chief Executive Officer, Executive Director, Member of the Executive Team) Auditors Deloitte & Associes NCYT Share Price Performance NCYT Share Price GBp 45.99p Day's Change 8.0 21.0% Traded 11:46am · Minimum 15 min delayed · NMS: 5.00k Volume 5,857,445 Bid - Ask 44.0 - 46.0 Low - High 50.0 - 50.0 Spread 435bps Avg Vol (3m) 181,859 Open - Close 43.5 - 38.0 12m Range 0.0 - 0.0 Beta 0.00 More » Latest NCYT News Announcements (delayed) Fri 7:11am Healthcare company Novacyt launches new coronavirus test 2nd Jan '18 Novacyt S.A. - Liquidity Agreement Update and Total Voting Rights 2nd Jan '18 RCS - Novacyt S.A. - PLACED IN TECHNOLOGY FAST 500 EMEA AWARDS 1st Dec '17 Novacyt S.A. - Liquidity Agreement Update and Total Voting Rights 7th Nov '17 Novacyt S.A. Legal & General Grp - Notification of major holdings Upcoming NCYT Events Recent ̄ s t Biotechnology & Medical Research Healthcare Industry Peer Group Profile Summary NCYT Share Price Quote Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as speciJcally authorised; and (c) are not warranted to be complete, accurate or timely. Broker Forecasts 31st Dec 2019 31st Dec 2020 Price Target: €0.85 (+88.01% above Price) Net Profit EPS DPS Net Profit EPS DPS Est. Long Term Growth Rate: n/a (€) (€) (€) (€) (€) (€) Consensus Estimate 2.20m 0.060 - 3.00m 0.14 - 1m Change - - - - - - 3m Change - - - - - - 1 Broker Broker Consensus Trend 2019 EPS Feb 2019 Apr 2019 Jun 2019 Aug 2019 Oct 2019 Dec 2019 Feb 2020 1 3 month 1 year 0% 200% 400% 600% Summit Therapeutic... Compare vs NCYT MaxCyte Inc Compare vs NCYT Yourgene Health Compare vs NCYT Faron Pharmaceutic... Compare vs NCYT Oxford Biodynamics Compare vs NCYT Circassia Pharmace... Compare vs NCYT Shield Therapeutic... Compare vs NCYT Bioventix Compare vs NCYT © Stockopedia 2020-02-03,12:04:43 You should independently research and verify any information that you Jnd in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suKer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2020 © Stockopedia 2020-02-03,12:04:43